• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$4.04 -$0.01 (-0.25%)

REAL-TIME: Last trade at

Corcept Therapeutics, Inc.

NASDAQ:CORT

What Should You Do With These 5 Skyrocketing Stocks?

Last Week's Top Stock Gainers

Company News for February 22, 2012 - Corporate Summary

US Stocks Mixed, Though Dow Cracks 13000

Don't Worry about Missing this 50% Pop

FDA Approves Corcept's Korlym Treatment For Cushing's Syndrome

The Big Bet on Corcept

Amgen, Vivus, Chelsea Therapeutics Prep for Key Catalysts in February

Regeneron Wins FDA Approval for Eye Drug: 3 Companies Up For Approval

Insider Picks: 5 Biotech Stocks Being Snapped Up By Insider Executives

7 Upcoming Biotech Catalysts

5 Stocks Under $5 With Conservative Accounting Practices

22 Companies With Market Cap Over $50 Million and 100%-Plus Sales Growth Forecast for 2011-12

9 Stocks Under $5 Dragged Down by Institutional Selling

20 Short Seller Targets Under $5

Neoprobe Looks to Become a Major Player in Oncology

Corcept Still Down but Positive Phase III Results Herald Potential Gains in 2011

Interview: Corcept Therapeutics CFO on Corlux Phase 3 Results

Four Biotechs Positioned for Strong 2010 Finish

December Will Be Exciting for Up and Coming Corcept Pharmaceuticals

The 20 Most Undervalued Biotech Stocks

Analyst Calls: CAH, EXPE, FSLR, HOT, LVS, MWW, NUVA, POT ...

20 Biotech Stocks Targeted by Short Sellers Over the Last 3 Months